Please login to the form below
Omicron
This page shows the latest Omicron news and features for those working in and with pharma, biotech and healthcare.
Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children
Pfizer and BioNTech’s Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine has been authorised by the US Food and Drug Administration (FDA) for emergency use as a single ... time. The partners have previously maintained that a fourth dose would ‘give
Latest news
-
JCVI recommends spring COVID-19 booster for those at highest risk
It has also recently outlined that an emergency surge vaccine response may be required if a new variant of concern emerges that has clinically significant biological differences from the Omicron variant.
-
Pfizer/BioNTech submit FDA application for Omicron-adapted booster for young children
the option to further protect their young children against more recently circulating Omicron sub lineages’. ... Spikevax vaccine, pre-clinical data for the booster and clinical trial data for its second Omicron-targeting bivalent booster, mRNA-1273.214.
-
NICE publishes final draft guidance recommending three COVID-19 treatments
Although the majority of the clinical evidence that is available for NICE to review is based on studies done before the emergence of the Omicron variant, the three treatments are recommended
-
Facts are stubborn things
vaccine manufactured for the BA.4/BA.5 Omicron subvariants?
-
AstraZeneca’s Evusheld not recommended by NICE for COVID-19 prevention
The drug did show some effectiveness against some older Omicron variants in in vitro studies, NICE said, but the studies ‘showed clearly’ that it did not protect against the current common
More from news
Approximately 39 fully matching, plus 78 partially matching documents found.
Latest Intelligence
-
Customers, content and change
Communication speed will continue to be key, and last month the UK gave Moderna its first approval in the world for its updated COVID-19 booster vaccine directed at the Omicron
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
What does the future hold for clinical trial recruitment?
This work is ongoing as the virus mutates; last month, it was announced that Pfizer and BioNTech had started clinical trials for a new Covid vaccine targeting the Omicron variant.
-
Top 10 things to consider when designing hybrid meetings
Although the Omicron variant of COVID-19 might have set back the full return to in-person meetings for now, there is no doubt that the future is hybrid.
-
Placing people at Lucid’s heart: Paul Cutler, Lucid Group's new Chief People Officer
What highlights have you had so far? I am lucky to have joined before Omicron took hold, and so was able to spend time across all of our UK offices getting
-
How to innovate and influence people in times of misinformation
vaccination effort, which left us more vulnerable to Delta-driven COVID surges in the summer and fall of 2021, as well as the Omicron variant that showed up toward the end
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Connectome competitiveness
- Humancomms for humancare?
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- Genmab hires first chief operating officer
- A relentless commitment to neuroscience
Latest intelligence
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
